A new study reports that men taking GLP-1 drugs such as Ozempic, Wegovy, or Zepbound may face a 7% greater chance of hair loss if they are already genetically predisposed to male-pattern baldness. The finding comes from an analysis that separated this effect from the rapid weight loss these medications typically cause.
Researchers note that thinning hair in these patients is not fully explained by the physical stress of shedding pounds. Instead, they suggest a direct biological connection between GLP-1 receptor activation and hair follicle function may be at play, though the exact mechanism remains unclear.
For men with a family history of baldness, the added risk is modest but worth discussing with a doctor when weighing treatment options. The study does not indicate a higher risk for women or for men without genetic susceptibility, but it underscores the need for personalized monitoring of side effects in this class of drugs.